Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutant Calreticulin in MPN: Mechanistic Insights and Therapeutic Implications.

Current hematologic malignancy reports - 8 Jan 2025

Faiz Mifra, Riedemann Merle, Jutzi Jonas S, Mullally Ann

Abstract excerpt

PURPOSE OF REVIEW: More than a decade following the discovery of Calreticulin (CALR) mutations as drivers of myeloproliferative neoplasms (MPN), advances in the understanding of CALR-mutant MPN continue to emerge. Here, we summarize recent advances in mehanistic understanding and in targeted therapies for CALR-mutant MPN. RECENT FINDINGS: Structural insights revealed that the mutant CALR-MPL complex is a tetramer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Calreticulin
Share to Eosinophilic Disorders and Syndromes

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Molecular Targeted Therapy

Share to Mutation

Share to Myeloproliferative Disorders

Share to Myeloproliferative Neoplasms: Diagnosis and Treatment

Share to Receptors, Thrombopoietin

Share to Signal Transduction

Source

Identifiers

PMID: 39775969
DOI: 10.1007/s11899-024-00749-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 21 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutant Calreticulin in MPN: Mechanistic Insights and Therapeutic Implications.PMID 39775969Read ↗

Mutant calreticulin in myeloproliferative neoplasmsSemantic proximity Read ↗

Mechanism underlying the development of myeloproliferative neoplasms through mutant calreticulinSemantic proximity Read ↗

Novel strategies targeting mutant calreticulin in essential thrombocythemia and myelofibrosis.Semantic proximity Read ↗

Calreticulin mutations in myeloproliferative neoplasms.Semantic proximity Read ↗

Selective targeting of mutated calreticulin by the monoclonal antibody INCA033989 inhibits oncogenic function of MPN.Semantic proximity Read ↗

Antibody targeting of mutant calreticulin in myeloproliferative neoplasms.Semantic proximity Read ↗

The role of calreticulin mutations in myeloproliferative neoplasms.Semantic proximity Read ↗

Defining the requirements for the pathogenic interaction between mutant calreticulin and MPL in MPNSemantic proximity Read ↗

Mutant Calreticulin in the Myeloproliferative NeoplasmsSemantic proximity Read ↗

Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation.Semantic proximity Read ↗

Immune Checkpoint Blockade Enhances Shared Neoantigen-Induced T-cell Immunity Directed against Mutated Calreticulin in Myeloproliferative NeoplasmsSemantic proximity Read ↗

Targeting the CALR interactome in myeloproliferative neoplasmsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.